Oh, I'm actually still a holder! Keeping a holding to take advantage of any SPP in the future. As I've said, I like the preclinical assets, but only at a valuation of $3m.
I agree RBx about the comms from Mautner; the real crash in SP is coming, they should have been pumping and slashing admin costs for the last 6 months. I suspect the next update about Veyonda might be the closure of the three trials and a pivot to a purely anti-inflammatory focus.
Oh, I'm actually still a holder! Keeping a holding to take...
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $23.08M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 59022 | 8.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.9¢ | 118764 | 1 |
View Market Depth
| Last trade - 11.08am 04/06/2024 (20 minute delay) ? |
| NOX (ASX) Chart |
Day chart unavailable